Ex vivo micro‑tumor testing

Accurately predicting clinical responses requires models that faithfully recapitulate the tumor microenvironment. VitroScan’s ex vivo micro‑tumor platform preserves native architecture, cellular heterogeneity, and stromal interactions of the patients’ tissues to deliver highly representative assays. By cultivating these patient-derived micro‑tumors in a physiologically relevant 3D matrix, our platform enables simultaneous evaluation of drug efficacy, resistance mechanisms, and combination strategies under conditions that closely mirror in‑situ disease.

More info

Translational insights to de-risk drug development

VitroScan integrates ex vivo micro‑tumor testing into a comprehensive solution that de‑risks drug development and accelerates the translation of new therapies into clinically relevant treatment options.

Near-clinical testing for impactful decision‑making

VitroScan’s ex vivo platform supports the development and clinical translation of innovative therapeutics through near clinical testing. By preserving tumor heterogeneity and the tumor microenvironment (TME), the platform enables modeling of patient-specific treatment responses. As a new approach methodology (NAM), it delivers insights that capture the real-world patient population. The platform’s predictive value helps to de-risk drug development, inform patient stratification for clinical trials, and helps to prevent late-stage failure of promising new therapies.

More info

Clinical trial program

VitroScan’s clinical trial program brings our ex vivo micro‑tumor platform directly into the clinic. The trials integrate patient‑derived micro‑tumor assays alongside traditional clinical endpoints. Eligible participants undergo minimally invasive tissue collection, enabling the generation of individualized micro‑tumors that are screened against investigational therapeutics, standard‑of‑care therapies, and rational combination regimens.

More info

VitroScan Team

Development driven by scientific experts

The VitroScan team, collaborating clinicians, and our investors are convinced that accurate prediction of true responders and non-responders to cancer drugs can substantially improve the care of cancer patients. Our team consists of highly motivated experts in oncology, cell biology, immunology, bioinformatics, and clinical trials. We collaborate with experts in the field to maximize the benefits of our technology platform, advance VitroScan’s development, and build a resilient, forward-looking organization.

Meet the team